Literature DB >> 32781168

Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B.

Sadaf Riaz1, Nabeel Abdulrahman2, Shahab Uddin3, Ayesha Jabeen4, Alain P Gadeau5, Larry Fliegel6, Fatima Mraiche7.   

Abstract

Previous studies have established the role of Na+/H+ exchanger isoform-1 (NHE1) and cathepsin B (Cat B) in the development of cardiomyocyte hypertrophy (CH). Both NHE1 and Cat B are activated under acidic conditions suggesting that their activities might be interrelated. The inhibition of NHE1 has been demonstrated to reduce cardiac hypertrophy but the mechanism that contributes to the anti-hypertrophic effect of NHE1 inhibition still remains unclear. H9c2 cardiomyoblasts were stimulated with Angiotensin (Ang) II in the presence and absence of N-[2-methyl-4,5-bis(methylsulphonyl)-benzoyl]-guanidine, hydrochloride (EMD, EMD 87580), an NHE1 inhibitor or CA-074Me, a Cat B inhibitor, and various cardiac hypertrophic parameters, namely cell surface area, protein content and atrial natriuretic peptide (ANP) mRNA were analyzed. EMD significantly suppressed markers of cardiomyocyte hypertrophy and inhibited Ang II stimulated Cat B protein and gene expression. Cat B is located within the acidic environment of lysosomes. Cat B proteases are released into the cytoplasm upon disintegration of the lysosomes. EMD or CA-074Me prevented the dispersal of the lysosomes induced by Ang II and reduced the ratio of LC3-II to LC3-I, a marker of autophagy. Moreover, Cat B protein expression and MMP-9 activity in the extracellular space were significantly attenuated in the presence of EMD or CA-074Me. Our study demonstrates a novel mechanism for attenuation of the hypertrophic phenotype by NHE1 inhibition that is mediated by a regression in Cat B. The inhibition of Cat B via EMD or CA-074Me attenuates the autosomal-lysosomal pathway and MMP-9 activation.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiotensin; Autophagy; Cardiomyocytes; Cathepsins; Hypertrophy; Matrix metalloproteinases

Mesh:

Substances:

Year:  2020        PMID: 32781168     DOI: 10.1016/j.ejphar.2020.173420

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

Review 1.  Na+/H+ Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure.

Authors:  Huiting Xia; Aqeela Zahra; Meng Jia; Qun Wang; Yunfu Wang; Susan L Campbell; Jianping Wu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15

2.  Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.

Authors:  Nabeel Abdulrahman; Meram Ibrahim; Jensa Mariam Joseph; Hanan Mahmoud Elkoubatry; Al-Anood Al-Shamasi; Menatallah Rayan; Alain Pierre Gadeau; Rashid Ahmed; Hussein Eldassouki; Anwarul Hasan; Fatima Mraiche
Journal:  Mol Cell Biochem       Date:  2022-03-25       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.